J&J/Cordis’ Cypher DES threatened by supplier dispute
This article was originally published in The Gray Sheet
Executive Summary
Wyeth sues Johnson & Johnson Oct. 26 in Delaware federal court, seeking to break an agreement to supply J&J's Cordis unit with sirolimus - the drug used on the Cypher drug-eluting stent. The suit alleges material breach of contract and seeks damages, charging Cordis with failing to make "commercially reasonable" efforts to develop CCI 779 - a drug analogous to sirolimus - as required under their agreement. Cordis denies the charges. A Wyeth spokesperson told "The Gray Sheet" that "if they don't act on [the agreement] over a period of time and they languish, [they should] terminate it so that we can find another partner." Wyeth advised Cordis of the charges in writing April 14, according to the complaint. Sirolimus is marketed by Wyeth as Rapamune...